Medpace has extensive experience in streamlining and accelerating clinical research in immunology, inflammation, and allergy.
Immunologic, inflammatory, and allergic diseases cause a significant burden to patients. There is a high unmet need for treatment options due to the complexities involved, as well as shared physiologic pathways across multiple indications and end organs. Streamline assets with broad indication potential by partnering with Medpace, an experienced, full-service CRO who can provide customized medical expertise across multiple therapeutic areas, including expertise in rare diseases and cell and gene therapies. Medpace has the medical leadership, trained staff, global trial experience, and site relationships to make your study a success.
Making the Complex Seamless® in Global Immunology, Inflammation, and Allergy Clinical Trials
Achieve quality results, meet deadlines, and maximize efficiencies by partnering with a full-service CRO that excels in designing and executing clinical research across a spectrum of immune-mediated inflammatory diseases (IMIDs). Medpace medical, operational, and regulatory expertise in immunology, inflammation, and allergy spans multiple therapeutic areas and indications, including dermatology, gastroenterology, oncology, ophthalmology, respiratory, and rheumatology. This extensive experience, coupled with cell and gene therapy expertise and a proven track record of success, ensures the ability to adapt to the unique needs of each trial and overcome the complexities associated with immune-mediated inflammatory diseases.
The intersection of immune-mediated inflammatory diseases (IMIDs) is handled through the collaboration of our medical leadership and functional areas. Medpace accelerates clinical development by fully embedding medical leadership and a wide array of relevant therapeutic expertise, integrated across all functional areas into the clinical trial process. Clinical immunologists are embedded within the trial to offer additional oversight. This cross-therapeutic and cross-functional area collaboration allows for optimized trial communication and execution, and ultimately, expedited timelines.
Explore our expert leaders who are shaping immunology research:
Brian Murphy, MD, MPH, FIDSA
Sr. Vice President, Medical Department
Board certified in infectious diseases, pediatrics, and internal medicine with over 25 years of experience as Medical Lead, Medical Monitor, or PI in Phase I-IV clinical trials, including 15 years at Medpace. An academic leader of multidisciplinary research teams across immunology and inflammation.
Kelly Metz, MD
Medical Director
Board-certified adult and pediatric allergist and clinical immunologist with over 20 years of clinical experience managing a broad spectrum of allergic and immunologic diseases. More than 5 years of Phase I-III clinical trial experience including allergic rhinoconjunctivitis, atopic dermatitis, celiac disease, chronic inducible urticaria, chronic spontaneous urticaria, eosinophilic esophagitis, hereditary angioedema, acquired angioedema, gene therapies, and pediatrics.
Maxime Jeljeli, MD, PhD
Medical Director
Board-certified clinical immunologist with over 13 years of combined clinical, academic, and pharmaceutical research experience in immunomodulatoy approaches including CAR T cells, monoclonal antibodies, immune cell reprogramming and gene-modifying strategies. Extensive expertise in the pathogenesis and clinical management of immune-mediated diseases, including chronic inflammatory disorders, allergy, autoimmunity, alloimmunity, chronic infections and onco-immunology.
Jack Bleesing, MD, PhD
Medical Director
Board-certified in adult and pediatric allergy/immunology with over 25 years of experience in clinical and applied immunology and pediatric blood diseases setting, focused on clinical/applied immunology, immune-oncology, and advanced therapeutics, including precision therapeutics, drug repurposing, and cellular and gene therapy.
Laura Omoboni, MS
Sr. Executive Director, Clinical Trial Management
Over 25 years of experience in the CRO industry across a wide variety of therapeutic areas, including immunology and inflammation, rheumatology, neuroscience, and rare diseases. She has strong global experience, including in advanced therapies.
Jill Adkins
Sr. Director, Clinical Trial Management
An accomplished Clinical Research Professional with more than 25 years of experience working in the drug development industry across all study phases and a broad range of therapeutic areas, including immunology and inflammation, rheumatology, dermatology, respiratory, and neuroscience. Areas of focus include placebo response mitigation, accurate pain reporting, and training of site staff and study participants to improve data quality in patient reported outcomes.
Jackie Widmer
Director, Clinical Trial Management
20 years of global industry experience leading Phase I-IV studies across multiple therapeutic areas, including immunology and inflammation, rheumatology, cell and gene therapies, and rare diseases. She has 15 years of Medpace global project management in progressive leadership roles.
“As a boarded Allergist/Immunologist, my role is to provide specialty expertise to trials by bridging clinical and trial experience in allergic and immunologic indications that cross therapeutic areas bound by common inflammatory pathways.”
Kelly Allred Metz, MD
Senior Medical Director, Medical Department, Medpace
The Medpace Advantage for Immune-Mediated Inflammatory Disease Trials
As a global full-service CRO with cross-functional collaboration and extensive experience, Medpace can support your clinical development through:
Extensive experience in biosimilars, combination therapies, cell and gene therapies, basket and platform designs, and new approaches for immunologic diseases
Providing comprehensive support via our dedicated global regulatory submissions and global regulatory affairs teams
Strategic guidance from our dedicated, in-house patient recruitment and retention teams who are experienced in recruiting patient populations, including clinical trials in rare diseases, to accelerate patient enrollment
Strong, long-term relationships with investigators, experienced sites, networks, and key opinion leaders (KOLs) help facilitate strategic site selection, start-up, and recruitment efforts
Broad expertise across indications, including but not limited to:
Allergic Conjunctivitis
Allergic Rhinitis
Alpha-1 Antitrypsin Deficiency
Amyloidosis
Asthma/COPD
Atopic Dermatitis
Celiac Disease
Chronic Rhinosinusitis with Nasal Polyps
Chronic Spontaneous Urticaria
Crohn’s Disease
Cystic Fibrosis
Eosinophilic Esophagitis
Hereditary Angioedema
Hidradenitis Suppurativa
IgG4-Related Disease
Inflammatory Bowel Disease
Interstitial Lung Disease
Mastocytosis
Psoriasis
Sarcoidosis
Systemic Lupus Erythematosus & Lupus Nephritis
Systemic Sclerosis
Strong Long-Standing Relationships
Medpace’s established relationships with global thought leaders, high-performing investigative sites, site networks, and patient advocacy organizations further strengthen recruitment and retention. This network helps facilitate strategic site selection, efficient start-up, targeted recruitment, and implementation of proven retention strategies—ensuring timely, high-quality enrollment that is key to the success of IMID programs.
Established Global Site Network
Strengthened by collaborative partnerships with our Flagship Sites and Centers of Excellence, Medpace offers Sponsors access to a global network of trusted, high-performing sites. With a deeply embedded global footprint, this network has proven experience delivering rapid study start-up, high-quality data, and reliable high enrollment.
Learn more about our Integrated Approach to Global Clinical Research
Streamline complex immunology and inflammation clinical trials with a full-service, single-vendor outsourcing strategy. Our comprehensive CRO services are supported by our wholly-owned Central Laboratories, Bioanalytical Lab, Imaging and ECG Core Lab, and Phase I Unit, as well as a ClinTrak®, a Clinical Trial Management System that ties all study data together in a single platform.
Central Laboratories
Medpace Central Labs provide consistency in methods and instrumentation across wholly-owned and purpose-built laboratories located in the US, Europe, China and Singapore. We offer safety testing as well as a wide range of inflammation and immunology-related biomarker assays, and can quickly establish and validate novel assays as needed. The team of hands-on laboratory PhD scientists are actively engaged with your study team throughout the entire clinical development process and collaborate with laboratory technologists and the project management team to seamlessly execute your trial.
Imaging Core Lab
Medpace Core Lab provides comprehensive central imaging services including site assessment, instrument/site qualification, and training and expert evaluation. Medpace delivers collaboration, training, and resource planning around the globe with consultation on imaging biomarker strategy for clinical development plans across immunology. Our imaging and clinical trial experience ensures that imaging components are seamlessly integrated into the complex structure of the overall trial.
Related Immunology, Inflammation, and Allergy Insights
